The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (NIH), is at the forefront for leading research to recognize, provide treatment, and prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has contributed to the development of new therapeutics that have improved the health of millions of people globally.
This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract No. HHSN272201600007I.
About Paragon Bioservices, Inc.
Paragon Bioservices is a private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon's cGMP facilities include microbial mammalian, fill-finish and fully-segregated virus facilities.
Philip Wills, VP Business Development
PH (410) 975-4050
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/niaid-awards-paragon-bioservices-a-multiple-award-idiq-contract-valued-up-to-159m-for-preclinical-drug-development-services-300392027.html
SOURCE Paragon Bioservices, Inc.